CCNE1 and B-cell chronic lymphocytic leukemia: Dinaciclib is currently being evaluated in a phase 3 clinical trial for chronic lymphocytic leukemia (CLL) and may have clinical potential in cyclin E1-dependent HGSOC as a chemosensitizing agent.